Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CETP | P11597 | 1/20 | 0.55 |
| ▸ | PDE10A | Q9Y233 | 7/20 | 0.53 |
| ▸ | MAPT | P10636 | 1/20 | 0.49 |
| ▸ | NQO1 | P15559 | 1/20 | 0.47 |
| ▸ | CA2 | P00918 | 1/20 | 0.47 |
| ▸ | GAA | P10253 | 1/20 | 0.44 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.43 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.43 |
| ▸ | MEN1 | O00255 | 2/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.43 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.42 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13021645 | 0.79 | NQO1 (0.64) | MAPTNQO1CA2CYP1A2CYP2A6 | |
| SCHEMBL2608797 | 0.78 | DHFR (0.44) | MAPTCA2GAAMEN1KMT2A | |
| SCHEMBL25205 | 0.76 | MAPT (0.67) | MAPTNQO1CYP1A2CYP2A6MEN1 | |
| SCHEMBL9634809 | 0.75 | LTA4H (0.68) | CETPPDE10ACYP1A2CYP2A6MEN1 | |
| SCHEMBL25798810 | 0.74 | PDE10A (0.59) | CETPPDE10ACYP1A2CYP2A6MEN1 | |
| SCHEMBL2838141 | 0.74 | CYP1A2 (0.65) | CYP1A2CYP2A6KMT2A | |
| SCHEMBL2614745 | 0.73 | CA12 (0.54) | MAPTNQO1CA2CYP1A2CYP2A6 | |
| SCHEMBL20414572 | 0.72 | CFD (0.51) | CA2GAA | |
| SCHEMBL5198075 | 0.72 | MAPT (0.51) | CETPPDE10AMAPTNQO1 | |
| SCHEMBL12657996 | 0.71 | ACHE (0.56) | MAPTNQO1GAACYP1A2CYP2A6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220216422-A1 | Electroluminescent Device | UDC IRELAND LTD (IE) | 2022-07-07 | — | — | US | disclosed |
| US-9923148-B2 | Electroluminescent device | UDC IRELAND LIMITED (IE) | 2018-03-20 | — | — | US | disclosed |
| US-20170194568-A9 | Electroluminescent Device | UDC IRELAND LIMITED (IE) | 2017-07-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220216422-A1 | Electroluminescent Device | PNPO, ODC1, AXL | CETP 4814/4885PDE10A 1638/4885MAPT 459/4885 |
| US-20170194568-A9 | Electroluminescent Device | DPYD, PNPO, TYMP | CETP 4701/4885PDE10A 1616/4885MAPT 900/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.